BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Drug Development

  BMS-Exelixis Combo Sustained 2-Year Survival for Kidney Cancer Patients

  Bristol Myers Squibb and Exelixis reported two-year follow-up data from the Phase III trial of BMS’s checkpoint inhibitor Opdivo (nivolumab) and Exelixis’ Cabometyx (cabozantinib).

  February 15, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Berlin Brothers Target New Day in AI Drug Discovery

  Terray Therapeutics has generated $60 million from a Series A financing round just shortly after getting $20 million in seed funding for the AI drug discovery.

  February 15, 2022

   · 

  3 min read

   · 

  Hayley Shasteen and Vanessa Doctor, RN
• 

  Business

  Investors Go with Their Gut, Dropping $236M into Kallyope

  Kallyope focuses on the gut-brain axis, a bi-directional communication between the gastrointestinal tract and the brain.

  February 15, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Money on the Move: February 9 – 15

  As the market seems to be taking a turn against biotech stock, more companies are opting for private funding instead of going public for the moment. And VC firms are happy to jump in.

  February 15, 2022

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Drug Development

  After a Rocky Week, TG Therapeutics Shares Some Good News

  After announcing that the FDA was investigating a possible death associated with its lymphoma drug Ukoniq (umbralisib), things are seemingly looking up for TG Therapeutics.

  February 15, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Proactive > Reactive: Science Targets Universal Coronavirus Vaccine

  While the “speed of science” to develop a successful coronavirus vaccine against the novel COVID-19 has been record-setting, scientists are telling us it’s not enough.

  February 15, 2022

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Business

  Three Big Antibody Research Collabs Hit the Wire

  Antibody research on cancer and neurological diseases is prioritized in series of biopharma research agreements.

  February 15, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Business

  Califf Wins Second Act as FDA Boss in Narrow Senate Vote

  After a filibuster was broken Monday, the Senate confirmed Califf’s nomination in a 50-46 bipartisan vote.

  February 15, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Genomenon Scores $1.7M SBIR Grant to Curate Genetic Drivers of Disease

  The grant is the latest in a steady stream of company advances highlighted by the addition of a chief financial officer in January and several collaborative agreements in the past year.

  February 15, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Business

  Califf Closes in on Second Stint as FDA Commissioner Despite Opposition

  Robert Califf’s nomination to resume his role as FDA Commissioner continues to advance in the Senate, despite some opposition from a key Democrat, Sen. Joe Manchin.

  February 15, 2022

   · 

  2 min read

   · 

  Alex Keown